UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1284-7
Program Prior Authorization/Notification
Medication Balversa® (erdafitinib)
P&T Approval Date 6/2019, 5/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Balversa (erdafitinib) is a kinase inhibitor indicated for the treatment of adult patients with
locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth
factor receptor 3 (FGFR3) genetic alterations whose disease has progressed on or after at least
one line of prior systemic therapy.
Limitations of Use:
Balversa is not recommended for the treatment of patients who are eligible for and have not
received prior PD-1 or PD-L1 inhibitor therapy.
The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium also
recommends the use of Balversa in the treatment of salivary gland tumor, pancreatic
adenocarcinoma, non-small cell lung cancer, invasive breast cancer, and cholangiocarcinoma.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Balversa will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Urothelial Carcinoma
1. Initial Authorization
a. Balversa will be approved based on ALL of the following criteria:
(1) Diagnosis of urothelial carcinoma
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
(2) Disease is one of the following:
(a) Locally advanced
(b) Metastatic
-AND-
(3) Presence of FGFR3 genetic alterations
-AND-
(4) Disease has progressed on or after at least one line of prior systemic therapy
[e.g., platinum-based chemotherapy (e.g., cisplatin, carboplatin), immune
checkpoint inhibitor (e.g., pembrolizumab, nivolumab, avelumab)]
-AND-
(5) One of the following:
(a) Patient has received prior systemic therapy containing an immune
checkpoint inhibitor (e.g., pembrolizumab, nivolumab, avelumab)
OR-
(b) Patient is not eligible for immune checkpoint inhibitor therapy (e.g.,
pembrolizumab, nivolumab, avelumab)
Authorization will be issued for 12 months.
2. Reauthorization
a. Balversa will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Balversa
therapy.
Authorization will be issued for 12 months.
C. Salivary Gland Tumor
1. Initial Authorization
a. Balversa will be approved based on ALL of the following criteria:
(1) Diagnosis of salivary gland tumor
-AND-
© 2025 UnitedHealthcare Services, Inc.
2
(2) Disease is one of the following:
(a) Recurrent
(b) Unresectable
(c) Metastatic
-AND-
(3) Presence of FGFR genetic alterations
-AND-
(4) Disease has progressed on or after at least one line of prior systemic therapy
[e.g., platinum-based chemotherapy (e.g., cisplatin, carboplatin)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Balversa will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Balversa
therapy.
Authorization will be issued for 12 months.
D. Pancreatic Adenocarcinoma
1. Initial Authorization
a. Balversa will be approved based on ALL of the following criteria:
(1) Diagnosis of pancreatic adenocarcinoma
-AND-
(2) Disease is one of the following:
(a) Locally advanced
(b) Metastatic
(c) Recurrent
-AND-
(3) Presence of FGFR genetic alterations
Authorization will be issued for 12 months.
2. Reauthorization
a. Balversa will be approved based on the following criterion:
© 2025 UnitedHealthcare Services, Inc.
3
(1) Patient does not show evidence of progressive disease while on Balversa
therapy.
Authorization will be issued for 12 months.
E. Non-Small Cell Lung Cancer
1. Initial Authorization
a. Balversa will be approved based on ALL of the following criteria:
(1) Diagnosis of non-small cell lung cancer
-AND-
(2) Disease is metastatic
-AND-
(3) Presence of FGFR genetic alterations
Authorization will be issued for 12 months.
2. Reauthorization
a. Balversa will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Balversa
therapy.
Authorization will be issued for 12 months.
F. Breast Cancer
1. Initial Authorization
a. Balversa will be approved based on ALL of the following criteria:
(1) Diagnosis of invasive breast cancer
-AND-
(2) Disease is metastatic
-AND-
(3) Presence of FGFR1-3 genetic alterations
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
4
2. Reauthorization
a. Balversa will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Balversa
therapy.
Authorization will be issued for 12 months.
G. Cholangiocarcinoma
1. Initial Authorization
a. Balversa will be approved based on ALL of the following criteria:
(1) Diagnosis of cholangiocarcinoma
-AND-
(2) Disease is one of the following:
(a) Unresectable
(b) Metastatic
-AND-
(3) Presence of FGFR2 genetic alterations
-AND-
(4) Disease has progressed on or after both of the following:
(a) Lytgovi (futibatinib)
(b) Pemazyre (pemigatinib)
Authorization will be issued for 12 months.
2. Reauthorization
a. Balversa will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Balversa
therapy.
Authorization will be issued for 12 months.
H. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
© 2025 UnitedHealthcare Services, Inc.
5
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Balversa [package insert]. Horsham, PA: Janssen Products, LP; October 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed March 21,
2025
Program Prior Authorization/Notification - Balversa
Change Control
6/2019 New program.
5/2020 Annual review. Updated reference.
5/2021 Annual review. Updated references.
5/2022 Annual review. Updated references.
5/2023 Annual review with no changes to coverage criteria. Added state
mandate footnote and updated references.
5/2024 Annual review. Removed coverage for FGFR2 genetic alterations.
Added that first line of prior systemic therapy should contain an
immune checkpoint inhibitor, if eligible. Updated background and
references.
5/2025 Annual review. Added coverage criteria for salivary gland tumor,
pancreatic adenocarcinoma, non-small cell lung cancer, breast cancer,
and cholangiocarcinoma. Updated background and references.
© 2025 UnitedHealthcare Services, Inc.
6